Molecular and Genetic Testing Before Targeted Therapy: How Tumor Markers Match the Drug

The biopsy was over in forty minutes. The waiting was not. A week later the pathology report confirmed a diagnosis, and then came a sentence that puzzled the whole family: “Tissue has been sent for molecular testing before targeted therapy can be considered.” Sent where? Tested for what? And why does a treatment plan now hinge on a lab the patient will never see?

That sentence is becoming routine in cancer care. A tumor is no longer described only by where it started and how far it has spread. It is also described by what has gone wrong inside its cells, down to a single misspelled letter in a gene. Some of those misspellings happen to be the exact thing a drug was built to block.

This explainer walks through what happens to that sample, which markers matter, how long the process usually takes, and what a result can and cannot tell you. The decisions stay with your treating team. The understanding can be yours.

Why would a biopsy be sent for molecular testing?

Under a microscope, two lung tumors can look identical: same cell shape, same growth pattern, same grade. Yet one may be driven by a fault in a gene called EGFR and the other by a rearranged gene called ALK. Those two cancers behave differently and respond to different medicines. Only molecular testing can tell them apart.

A biomarker is any measurable feature of a tumor that gives information about how it behaves or how it might respond to treatment. Molecular testing looks for biomarkers at the level of DNA, RNA and protein. The National Cancer Institute describes this as the step that lets a doctor choose a treatment matched to the specific changes in a person’s cancer, rather than to the cancer type alone.

So the biopsy is sent on for three practical reasons. The first is drug matching: several targeted medicines are only prescribed when a defined marker is present, because they do little or nothing without it. The second is avoidance: a result can show that a particular drug class is unlikely to help, sparing someone side effects for no benefit. The third is clarity: in some cancers, such as gliomas and thyroid nodules, molecular features now help refine the diagnosis itself.

None of this means the original pathology report was incomplete. Think of it as two layers of the same story. Conventional pathology says what kind of cancer this is. Molecular testing says what is driving it. Treatment planning increasingly needs both, which is why many centers now order the molecular tests automatically, a practice known as reflex testing, so that results are ready when the team meets to discuss options.

What is targeted therapy, and why does it need a matching marker?

Traditional chemotherapy works largely by damaging any cell that divides quickly. That includes cancer cells, but also hair follicles, the gut lining and bone marrow, which is why its side effects are so familiar. Targeted therapy takes a narrower aim. It interferes with a specific molecule that the cancer depends on, often a protein produced by a faulty gene.

The National Cancer Institute groups most targeted drugs into two broad types. Small-molecule drugs are tiny enough to slip inside a cell and jam a signaling protein, for instance a tyrosine kinase, which is an enzyme that passes “grow now” messages along a chain. Monoclonal antibodies are larger, lab-made proteins that attach to targets on the outside of a cell, either blocking a receptor or flagging the cell for the immune system.

The logic is simple. A drug designed to block an overactive HER2 protein can only help if the tumor is making excess HER2. A drug that fits a mutated form of a kinase does nothing useful if the kinase is normal. The marker and the medicine are, quite literally, matched pieces.

This explains why molecular testing is often described as a gate rather than an extra. Prescribing a targeted drug without confirming its target would be like replacing a car part before checking which part has failed. In practice, regulators and clinical guidelines tie many targeted medicines to a specific test result, sometimes called a companion diagnostic, a lab test that must be positive before a particular drug is considered.

Targeted therapy is not gentler by definition. It has its own side effects, which depend on what the target normally does in healthy tissue. Skin, liver, blood pressure and the heart are common sites. Your oncology team weighs those against the expected benefit for your specific marker.

How molecular testing before targeted therapy actually works

Start with the sample. Most molecular testing is performed on tissue removed at biopsy or surgery, which the pathology lab has already fixed in formalin and embedded in a block of paraffin wax. A technician cuts slices a few thousandths of a millimeter thick. Some slices go on glass slides for staining; others are scraped into tubes so DNA and RNA can be extracted.

From there, the route depends on the question being asked. If the team needs to know whether a protein is present and how abundant it is, immunohistochemistry (IHC) is used: an antibody that sticks to the protein is applied to the slide, linked to a dye, and the pathologist scores how strongly and how widely the tissue stains. If the question is whether a gene has been amplified or rearranged, fluorescence in situ hybridization (FISH) uses glowing probes that light up the gene’s location in each cell’s nucleus, so extra copies or broken-and-rejoined segments become visible as patterns of colored dots.

When many genes need checking at once, labs use next-generation sequencing (NGS), a method that reads millions of short stretches of DNA or RNA in parallel and compares them with a reference genome. Software flags differences: a single-letter substitution, a deleted segment, a fusion of two genes that are normally far apart, or a count of mutations across the whole panel.

Every flagged change is then reviewed by a molecular pathologist, who asks three things. Is this a genuine alteration or a technical artefact? Is it already known to affect cancer behavior or drug response? And is there an approved or guideline-supported drug that acts on it? The answers are written into a report that joins the main pathology file and is discussed at a multidisciplinary meeting, where oncologists, pathologists, radiologists and surgeons agree on options to present to you.

Tumor markers, biomarkers, mutations: sorting out the words

The vocabulary around biomarker testing for cancer is genuinely confusing, partly because different specialties use overlapping terms. A quick glossary helps.

A tumor marker, in the older sense, is a substance measured in blood or urine that a cancer releases or provokes, such as PSA in prostate cancer or CA-125 in ovarian cancer. MedlinePlus notes these are useful for monitoring, but they rarely decide which targeted drug to use, and non-cancer conditions can raise them too.

A biomarker is the broader modern term covering any measurable feature, including those classic blood tests but also DNA changes, RNA fusions and protein levels inside the tumor itself. When oncologists say “we are waiting on your biomarkers,” they almost always mean tissue-based molecular results.

A mutation is a change in the DNA sequence of a gene. A driver mutation is one that actively pushes cancer growth; a passenger mutation is along for the ride and usually has no treatment implications. Targeted therapy is built around drivers.

An amplification means a gene is present in far more copies than the normal two, so the cell makes too much of its protein. A fusion means two genes have been joined, producing a hybrid protein stuck in the “on” position. Expression refers to how much of a protein a cell is producing, which is what IHC measures.

Finally, there are markers that predict response to immunotherapy rather than classic targeted drugs: PD-L1 expression, tumor mutational burden (the total count of mutations per stretch of DNA) and microsatellite instability (a sign that the cell’s DNA-repair spell-checker is broken). These usually sit on the same report, which is why the document can run to several pages. If a term on yours is unfamiliar, it is reasonable to ask the team to translate each line into what it changes about your options.

Which molecular tests are used? Single gene, panels, IHC and FISH compared

No single method answers every question, so labs mix techniques. The right combination depends on the cancer type, how much tissue exists and how urgently a result is needed. The table below summarizes the main approaches and what each is good at; it is a general guide, not a menu you choose from.

Method	What it detects	Typical strengths	Common limits
Immunohistochemistry (IHC)	Protein presence and amount on a slide	Fast, inexpensive to run, widely available, shows which cells stain	Scoring has some observer variation; does not read DNA
FISH	Gene amplification, deletion or rearrangement	Visual confirmation at the single-cell level; long-established for HER2 and ALK	One or two genes per test; needs interpretable nuclei
Single-gene PCR	Specific known mutations in one gene	Quick turnaround, very sensitive for the targets it covers	Misses anything it was not designed to look for
NGS panel (DNA)	Dozens to hundreds of genes: mutations, copy changes, mutational burden	Broad view from one sample; can reveal unexpected targets	Longer turnaround; needs adequate tumor content
NGS panel (RNA)	Gene fusions and splicing changes	More reliable than DNA for fusions	RNA degrades in stored tissue; not every lab offers it
Liquid biopsy (ctDNA)	Tumor DNA fragments in blood	No new procedure; can track change over time	Can miss low-shedding tumors; a negative result is less conclusive

Guideline bodies increasingly favor broad NGS panels for cancers with many possible drivers, such as non-small cell lung cancer, because testing genes one at a time can exhaust a small biopsy before all relevant markers are checked. For cancers where one or two markers dominate, a focused IHC or FISH test may be entirely sufficient. The pathologist chooses the sequence to protect the tissue and answer the most treatment-relevant questions first.

Liquid biopsy vs tissue biopsy: when blood can stand in for tissue

Tumors shed fragments of their DNA into the bloodstream as cells die. A liquid biopsy captures those fragments, called circulating tumor DNA or ctDNA, from an ordinary blood draw and sequences them. For someone who is too unwell for another needle procedure, or whose tumor sits somewhere hard to reach, the appeal is obvious.

The evidence supports liquid biopsy in defined situations rather than as a universal substitute. The National Cancer Institute’s overview of biomarker testing notes that blood-based tests can identify treatable alterations and are especially useful when tissue is insufficient. Guidelines for several cancers now accept a positive ctDNA finding as adequate to guide a targeted drug, provided the result is a well-validated marker.

The catch lies in the negative result. Some tumors release very little DNA into blood, particularly smaller or slower-growing ones and some brain tumors behind the blood-brain barrier. A liquid biopsy that finds nothing therefore cannot rule out a driver mutation; most guidelines recommend following a negative blood test with tissue testing when tissue can be obtained. Clinicians sometimes summarize this as “a positive liquid result is actionable, a negative one is unfinished.”

Liquid biopsy also has roles beyond the first treatment decision. Because it can be repeated easily, it is used to look for resistance mutations when a targeted drug stops working, and it is being studied for detecting leftover disease after surgery. Those research uses are promising but not yet standard everywhere, and your team will tell you which apply to your situation.

Tissue remains the foundation. It allows pathologists to see the architecture of the tumor, measure protein expression directly and confirm how much of the sample is actually cancer. Blood complements that picture; it rarely replaces it outright.

Who is usually tested, and who is usually asked to wait

Molecular testing is now recommended at diagnosis for a growing list of cancers where a result changes first-line treatment. Non-small cell lung cancer, colorectal cancer, melanoma, breast cancer, certain leukemias, gastrointestinal stromal tumors, thyroid cancers that resist standard treatment, ovarian cancer and many brain tumors are among the clearest examples in current national and international guidance. In these settings the test is ordered routinely, not because someone asked.

Testing is also typically offered when a cancer has spread or returned after earlier treatment, even if the original tumor was never profiled, because the options at that point often include marker-dependent drugs. Cancers of unknown primary, where the starting organ cannot be identified, are another common trigger, since a molecular profile can sometimes point to both the origin and a treatment.

Who is asked to wait? Several groups, for sensible reasons. People with very early, small, completely removed tumors in cancer types where no targeted drug is used at that stage may not be tested immediately; the tissue is stored and can be tested later if ever needed. Someone whose biopsy contains too little tumor may be asked to wait for a repeat sample or a blood-based test rather than receive an unreliable result. And when a person is acutely unwell, the team may begin a standard treatment that does not depend on markers while results are pending, then adjust once they arrive.

A few people are not candidates for targeted therapy regardless of markers, because of organ function, interacting medicines or personal preference, and the team may still test to inform prognosis or family risk. Eligibility is never decided by the lab report alone. Fitness, goals of care, other health conditions and the person’s own priorities are weighed together, which is exactly why the result lands on a multidisciplinary table before it reaches a prescription pad.

At what stage of cancer is targeted therapy used?

The honest answer is: it depends on the cancer, the marker and the evidence for that specific pairing. Targeted therapy began mostly in advanced disease, where tumors have spread and chemotherapy alone offered limited control. Much of the strongest evidence still sits there, and for many cancers a biomarker-matched drug is now a standard first-line option for metastatic disease.

That picture has shifted in recent years. In some cancers, targeted drugs have moved earlier, into the adjuvant setting, meaning treatment given after surgery to reduce the chance of recurrence, or the neoadjuvant setting, meaning treatment given before surgery to shrink a tumor. HER2-directed antibodies in early breast cancer and kinase inhibitors after resection of certain mutation-positive lung cancers are examples described in national guidance. In chronic myeloid leukemia, a targeted drug class became the backbone of treatment from diagnosis onward.

Because of this spread across stages, guideline groups now recommend molecular testing at diagnosis for many cancers even when the disease appears localized. The reasoning is practical: if a marker would change what happens after surgery, it is better to know before the operation than to retrieve archived tissue months later under time pressure.

Stage and biomarker remain separate facts. Stage describes how far a cancer has traveled; a molecular result describes what is driving it. A person with a stage I tumor and a person with stage IV disease can share the same mutation and be offered the same drug class, though for different purposes and durations. Equally, a stage IV cancer with no actionable marker will be treated with the non-targeted options appropriate to that stage.

Your oncologist can tell you, for your cancer type and stage, whether a marker-matched drug is standard, optional, investigational or not applicable. That conversation is more useful than any general rule.

How long does molecular testing take? The days and weeks after the biopsy

The waiting is often the hardest part, so it helps to know what fills the time. The sequence below describes a typical pathway; your center may differ.

In the first few days, the tissue is processed and the pathologist confirms the diagnosis and estimates how much of the sample is tumor. A sample that is mostly scar, inflammation or normal tissue may not yield enough tumor DNA, and the team may decide early on to request another sample or a blood test.

Quick tests tend to come next. IHC results, including hormone receptors, HER2 and PD-L1, are frequently available within a few days. Single-gene tests follow a similar rhythm. According to the National Cancer Institute’s guidance on biomarker testing, overall results can take anywhere from several days to a few weeks depending on the type of test and whether the sample is sent to an outside laboratory.

Broad NGS panels sit at the longer end of that range. Extraction, sequencing, computer analysis and expert review each add time, and many hospitals send panels to specialist reference labs, which adds transport and queueing. If RNA fusion testing is required, that may run in parallel or afterward.

What happens to you during this window varies. Some people start a non-marker-dependent treatment immediately if the cancer is causing symptoms. Others use the weeks for staging scans, fertility discussions, dental checks or surgery, so that when results arrive the plan can start without further delay. Many centers schedule the treatment-decision appointment for the expected result date rather than leaving it open.

It is reasonable to ask two questions at the outset: which tests have been ordered, and roughly when each is expected back. If results run late, the usual causes are insufficient tumor in the sample, a technical failure requiring a repeat run, or a backlog at the external lab. None of those means anything has been found.

Reading the report: what a result does and does not mean

A molecular report usually has three parts: alterations with a clearly linked treatment, alterations of known significance without a matched drug, and variants of uncertain significance, meaning DNA changes whose effect is not yet understood. Most reports also list the markers tested and found normal.

An “actionable” finding means a drug exists that acts on that marker and has evidence in some setting. It does not guarantee the drug is approved for your cancer type, that you are eligible, or that it would work in your case. Response rates in trials describe groups, not individuals, and your team will discuss what the evidence for your specific pairing actually shows.

A negative or “no actionable alteration” result is not a dead end. It means the tested markers were absent or the sample was inadequate; the report should say which. Standard treatments, immunotherapy where appropriate and clinical trials remain on the table.

One line deserves special attention: the distinction between somatic and germline findings. Somatic changes arise in the tumor only and are not passed on. Germline changes are inherited, present in every cell, and may raise cancer risk for relatives. Tumor-only testing can hint at a germline change, for example a BRCA alteration, but cannot confirm it. The NHS explains that confirming an inherited variant requires a separate blood or saliva test, usually arranged with genetic counseling so that implications for family members are discussed properly.

Results can also change over time. Cancers evolve under treatment, and a tumor that progresses after months on a targeted drug has often acquired a new resistance mutation. Retesting at that point, by tissue or blood, is now standard in several cancers because the next option may depend on exactly how the cancer escaped. A report, in other words, is a snapshot of one moment, not a permanent label.

How accurate is molecular testing? The thyroid nodule example

Accuracy has two sides. A test’s sensitivity is how well it catches a change that is truly present; its specificity is how well it avoids false alarms. Modern sequencing is technically precise: when a well-validated lab reports a known driver mutation in a sample with enough tumor, that finding is highly reliable. Most real-world uncertainty comes from the sample, not the sequencer, which is why reports state the estimated tumor fraction.

Thyroid nodules show a different kind of accuracy question. Many are biopsied by fine needle and return an “indeterminate” result, meaning the cells look neither clearly benign nor clearly cancerous. Historically, most people in that group had surgery to find out, and the majority turned out to have benign disease. Molecular tests on the needle sample were developed to reduce that uncertainty.

What does the evidence show? Current molecular classifiers perform well at ruling cancer out: a benign molecular result in an indeterminate nodule carries a low chance of malignancy, and professional thyroid guidelines accept it as a reason to monitor rather than operate in suitable cases. They are less decisive at ruling cancer in. A “suspicious” molecular result still includes a meaningful share of benign nodules, so it informs the decision to operate rather than settling it. Published performance figures vary between test versions and between populations, because the predictive value of any test shifts with how common cancer is in the group being tested. For that reason, this article does not quote a single percentage; your endocrinology team can tell you what the specific test they use has shown in nodules like yours.

The broader lesson applies to every cancer. Accuracy is never a single number printed on the box. It depends on the sample, the laboratory’s validation, the specific marker and the population. Asking “how well does this test perform for my question” is more useful than asking whether a test is accurate in the abstract.

What people often get wrong about molecular testing before targeted therapy

Myth one: every cancer has a targeted drug waiting to be matched. The reality is that many tumors show no alteration with an available drug, and for several common cancers the proportion with an actionable driver is a minority. A clean report is common and does not mean the testing was wasted; ruling out a target is itself information.

Myth two: targeted therapy means no side effects. Blocking a protein the body also uses for normal functions has consequences. Rashes, diarrhea, raised blood pressure, liver enzyme changes and heart effects are well-described with different drug classes. The side effect profile is different from chemotherapy, not absent.

Myth three: “genetic testing” means the cancer is inherited. Most changes found in tumor testing are somatic, acquired during life by that tumor alone. Only a confirmed germline test, performed on normal cells, speaks to inherited risk.

Myth four: a liquid biopsy is just a better, easier version of a tissue biopsy. It is easier, and often valuable, but a negative blood test cannot exclude a target. Tissue remains the reference standard when it can be safely obtained.

Myth five: the test tells you how long you have. Molecular reports describe drug targets and sometimes prognostic markers, but they do not produce a timeline, and reputable teams will not present them as one.

Myth six: once tested, always tested. Tumors change under treatment pressure. Retesting after progression is a normal part of care in several cancers, not a sign that the first test was wrong.

Myth seven: a bigger panel is always better. Broad panels are powerful, but in a cancer with one or two dominant markers, a focused test may be faster and conserve tissue. The pathologist’s choice reflects your cancer type, not a shortcut.

Each of these misunderstandings tends to surface in the gap between biopsy and results. Asking your team to walk through the report line by line is the most reliable way to close it.

Questions to ask your care team

A good consultation about molecular results is a conversation, not a reading. These prompts can help you steer it. You do not need to ask all of them, and it is fine to bring a written list or a companion to take notes.

• Which molecular tests have been ordered on my sample, and what is each one looking for?
• Was there enough tumor in my biopsy for reliable testing, or might a repeat sample or a blood test be needed?
• Roughly when do you expect each result, and will we meet to discuss them or will I hear by phone?
• Did my tumor show any alteration that has a matched drug? Is that drug standard for my cancer type and stage, or would it be a trial or off-label option?
• If no actionable marker was found, what are my treatment options, and does the result change the plan at all?
• Were any variants of uncertain significance reported, and will the lab update us if their meaning becomes clearer?
• Does anything in my tumor result suggest an inherited change? Should I be referred for germline testing and genetic counseling?
• Will the sample be stored so that it can be retested later if the cancer changes?
• If I start a targeted drug, what side effects should I watch for, and which ones mean I should call the same day?
• How will we know whether the drug is working, and what happens if the cancer progresses while I am on it?
• Is there a clinical trial that uses my specific marker, and would I be eligible?
• Can I have a copy of the molecular report, and would you mark the lines that matter most?

Teams generally welcome these questions. They signal that you want to be an active partner in the decision, and they often surface practical details, such as storage of leftover tissue, that otherwise go unmentioned. If an answer is “we don’t know yet,” that is a legitimate answer in this field; ask when you might know, and what will happen in the meantime.

When to call your doctor

Molecular testing itself involves no new procedure once the sample exists, but the biopsy that produced it and any targeted therapy that follows both carry risks that deserve prompt attention. Contact your oncology team or seek urgent care if you notice any of the following.

After a biopsy, call the same day for bleeding that soaks through a dressing or does not stop with firm pressure, spreading redness, warmth or pus at the site, a fever, or pain that worsens rather than eases. After a lung or liver biopsy in particular, new shortness of breath, chest pain or coughing up blood needs emergency assessment, since these can signal a collapsed lung or internal bleeding.

Once targeted therapy begins, your team will give you a specific list, because each drug class has its own warning signs. Common red flags across classes include a temperature at or above the threshold your team specifies, severe or persistent diarrhea, a widespread or blistering rash, yellowing of the skin or eyes, dark urine, sudden swelling of the face or legs, new breathlessness or a dry cough that does not settle, chest pain or palpitations, severe headache or confusion, and any sudden change in vision. Several targeted drugs can affect the heart or raise blood pressure, so unexplained dizziness or fainting also warrants a call.

While waiting for results, the main reasons to call are new or rapidly worsening symptoms from the cancer itself: unrelenting pain, difficulty breathing, inability to keep fluids down, new weakness in a limb, or seizures. Treatment can be started before molecular results are back if the situation demands it; the team needs to know how you are.

Keep the oncology helpline number where you can find it, and do not hesitate because you are unsure whether something counts. In this setting, the team would far rather hear from you early. Every decision about pausing, adjusting or continuing a medicine sits with your treating clinicians, who know your results and your history.

Frequently asked questions

Why would a biopsy be sent for molecular testing?

A biopsy is sent for molecular testing to find changes in the tumor’s genes or proteins that can determine which drugs are likely to work. Standard pathology identifies the cancer type; molecular testing identifies what is driving it. For many cancers, including lung, colorectal, breast and melanoma, guidelines recommend this step at diagnosis because the result can change first-line treatment or rule out drugs that would not help.

What is biomarker testing for cancer, and is it the same as genetic testing?

Biomarker testing for cancer measures features of a tumor, such as mutations, gene fusions, amplifications or protein levels, that predict behavior or drug response. It overlaps with genetic testing but is not identical. Tumor biomarker testing looks at changes acquired by the cancer cells; hereditary genetic testing looks at changes present in every cell since birth. A tumor test can hint at an inherited change, but a separate germline test is needed to confirm it.

How long does molecular testing take?

Results typically arrive within days for quick tests such as immunohistochemistry and single-gene assays, and within a few weeks for broad sequencing panels, according to the National Cancer Institute. Timing depends on how much tumor the sample contains, whether RNA fusion testing is added, and whether the sample travels to an outside laboratory. Your team can tell you which tests were ordered and roughly when each is expected.

At what stage of cancer is targeted therapy used?

Targeted therapy is used most often in advanced or metastatic cancer, where much of the evidence sits, but for several cancers it is now also given before or after surgery in earlier stages when a specific marker is present. Examples in national guidance include HER2-directed treatment in early breast cancer and kinase inhibitors after removal of certain mutation-positive lung cancers. Whether it applies to your stage depends on your cancer type and marker.

How accurate is molecular testing for thyroid cancer?

Molecular tests on indeterminate thyroid nodules are reliable at ruling cancer out: a benign molecular result carries a low likelihood of malignancy and guidelines accept it as a reason to monitor rather than operate in suitable cases. They are less decisive at confirming cancer, since a suspicious result still includes some benign nodules. Performance varies by test and population, so ask your endocrinology team what their specific test has shown.

What is targeted therapy in simple terms?

Targeted therapy is a cancer treatment that blocks a specific molecule the cancer depends on, often a protein made by a faulty gene, rather than attacking all fast-dividing cells the way chemotherapy does. Small-molecule drugs act inside the cell; monoclonal antibodies attach to targets on the surface. Because the drug fits one target, a test confirming that target is usually required before it is considered.

Liquid biopsy vs tissue biopsy: which is better for molecular testing?

Tissue remains the reference standard because it lets pathologists see tumor architecture, measure protein expression and confirm tumor content. Liquid biopsy, which sequences tumor DNA fragments in blood, is valuable when tissue is scarce or a new procedure is risky, and a positive result can guide treatment. A negative liquid result cannot exclude a target, so guidelines usually recommend tissue testing afterward when feasible.

What does it mean if no actionable mutation is found?

It means the markers tested were absent, or the sample contained too little tumor for a reliable read; the report should state which. It does not mean treatment options are exhausted. Standard chemotherapy, immunotherapy where appropriate, radiation, surgery and clinical trials remain available. Your team may also recommend retesting later, since tumors can acquire new alterations over time.

Can molecular testing be repeated if the cancer comes back?

Yes, and in several cancers it is standard practice. Tumors evolve under treatment pressure and often develop resistance mutations that determine the next option. Retesting can use a new tissue biopsy or a blood-based liquid biopsy. This is one reason labs store leftover tissue and why it is worth asking whether your sample will be kept.

Does a tumor mutation mean my children are at risk?

Usually not. Most mutations found in tumor tissue are somatic, acquired by the cancer cells alone and not passed on. Some findings, such as alterations in BRCA or mismatch-repair genes, can occasionally reflect an inherited change. If your report raises that possibility, your team may refer you for germline testing with genetic counseling, which is the only way to confirm hereditary risk and discuss implications for relatives.

References

• MedlinePlus: Tumor Marker Tests
• NHS: Genetic and genomic testing
• Cleveland Clinic: Targeted Therapy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.